News / Asia

Patent Dispute Threatens Access to Cheap Drugs in India

Indians suffering from HIV/AIDS attend a protest against the drugs manufacturer Novartis in New Delhi, India, January 29, 2007. Novartis is challenging a specific provision of the law that restricts the patenting of medicines to innovations only. Indians suffering from HIV/AIDS attend a protest against the drugs manufacturer Novartis in New Delhi, India, January 29, 2007. Novartis is challenging a specific provision of the law that restricts the patenting of medicines to innovations only.
x
Indians suffering from HIV/AIDS attend a protest against the drugs manufacturer Novartis in New Delhi, India, January 29, 2007. Novartis is challenging a specific provision of the law that restricts the patenting of medicines to innovations only.
Indians suffering from HIV/AIDS attend a protest against the drugs manufacturer Novartis in New Delhi, India, January 29, 2007. Novartis is challenging a specific provision of the law that restricts the patenting of medicines to innovations only.
Anjana Pasricha
NEW DELHI — A long running legal battle in India over drug patents could impact access to affordable, lifesaving drugs to millions of people across the globe. 

The case is being seen as a high stakes battle between drug companies supporting intellectual property rights and those who favor the production of cheap, generic drugs.   
Dr. Suniti Solomon has treated thousands of men and women suffering from HIV at her clinic in the southern city of Chennai since she detected India’s first AIDS infection 25 years ago. Affordable copies of brand name drugs produced by India’s booming generic drug industry have helped her patients enormously.   
 
“Earlier, when we did not have generic drugs, maybe one or two percent of my patients could afford the drugs from abroad," Solomon said. "Now, 60 to 70 percent can easily afford at least the first line drugs which keep them alive for maybe ten years or longer.”
 
Like the patients in Chennai, these generic drugs are a lifeline for millions of people in Africa and other developing countries.
 
Many of them are not aware of it, but a case pending before the Indian Supreme Court could have a far reaching impact on their access to these inexpensive drugs. 

It involves a legal challenge by Swiss pharmaceutical company Novartis to India’s refusal to grant a patent for a medicine used to treat leukemia. It has been winding its way through the Indian courts for almost six years. Final arguments will be heard next month.  
 
India denied a patent for Gleevec saying that it is not a new medicine but a salt formulation of a known drug. India does not allow companies to patent modifications of an old medicine unless its efficacy is significantly improved.
 
Forty countries, including the United States, China and Russia, have granted a patent for Gleevec. But in India, its generic version is being produced at a fraction of the cost.
 
Novartis says it is seeking clarity on how innovation by the drug industry will be protected in India. Ranjit Shahani, who heads the India operations of Novartis, says inadequate patent protection will discourage innovators.  
 
“The long road to innovation research is fraught with risks and huge costs," Shahani said. "Only one out of ten thousand experimental compounds in development will reach the marketplace and the cost is between one to two billion dollars for each medicine approved. A successful molecule that makes it as a drug needs to pay for thousands of those molecules that fail.”
 
The case has attracted international attention. The multinational drug industry sees the Indian law as a way of circumventing patent rights and wants more stringent standards.
 
However, supporters of India’s patent law say that it prevents a practice called “evergreening,” in which drug companies get new patents by making minor changes to older ones and stave off generic competition.
 
Leena Menghaney, a lawyer with Doctors Without Borders in New Delhi, calls it a test case.   
 
“If Novartis wins, it can have a huge chilling effect on generic production. Once patenting standards are lowered, that means more patents are granted on drugs, that means less number of drugs generic companies will be able to manufacture. So it has implications across the board for all essential medicines, particularly for HIV,” Mengheny said.
 
Health activists fear that a ruling in favor of Novartis may drastically reduce the global supply of inexpensive, generic drugs being used to treat people suffering from deadly diseases. They say if costs rise greatly, voluntary groups across the world will have to significantly scale down programs assisting patients who cannot afford lifesaving medicines.
 
One such patient is a 23-year-old student in Mumbai, Siddhesh Tilekar. Since he was diagnosed with cancer about three years ago, he gets drugs from a local cancer support group.
 
“We cannot afford that much of cost," Tilekar said. "If my family spends on my medicine, it is very difficult for us to survive.”
 
Multinational drug companies are worried about other provisions in India’s patent law.

Earlier this year, India allowed a domestic company to manufacture an expensive anti-cancer drug developed by Bayer Corporation using a rule under which a license can be granted if a drug is not available at a “reasonably affordable price.”  
 
According to Ranjit Shahani at Novartis, protecting patents is critical.
 
“The reality is without patents there will be no new drugs and without new drugs there will be no generics," he said. "So if innovation is not protected, it is the patient who will be the ultimate loser.”
 
Lawyers say there are also worries that India’s patent laws could become a model for other developing countries, limiting the multinational drug industry’s access to these fast-growing markets.

You May Like

Multimedia Social Media Documenting, Not Driving, Hong Kong Protests

Unlike in Arab Spring uprisings, pro-democracy protesters in Hong Kong aren't relying on Twitter and Facebook to organize, but social media still plays a role More

Bambari Hospital a Lone Place of Help in Violence-Plagued CAR

Only establishment still functioning in CAR's second city is main hospital More

This forum has been closed.
Comment Sorting
Comments
     
by: patent litigation from: Mexico
July 23, 2012 4:01 AM
Compulsory licensing is a contemporary necessity, and I'm glad to see countries from Australian to China implementing this model. I, for one, am heartened not only by the Indian Patent Office's recent decision to grant a compulsory license, but also by the further news that India now has plans to distribute some life-saving drugs for free. That -- and not gouging suffering patients at every possible opportunity -- seems to me to be the epitome of corporate responsibility.
http://www.generalpatent.com/blog


by: C Karen Stopford from: Connecticut
July 21, 2012 8:38 AM
What the pharmaceutical companies are saying is patently (no pun intended) false. Not every country lives by the American ethos of "profit at all costs." Why, believe it or not, there are some places in the world where human life has a value greater than a big credit limit. And innovation occurs in these places because people are respected, valued, allowed to explore and learn and satisfy their curiosity, and because people want to help other people. In fact, that's where most innovations come from. Not in America, of course - but elsewhere. Our system is cruel, unjust, immoral and unethical - and we will bully every other country in the world to do as we do - or else. Let 'em die! We need a profit!

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
The Legacy of Jimmy Carter: The Preacher from Plainsi
X
October 01, 2014 10:45 AM
It is common in the United States to see tourists flock to sites associated with America's presidents. Some are privately owned and others are run by the National Park Service or the National Archives -- but most have helped draw business and people into the towns and cities where they are located. As VOA’s Kane Farabaugh reports, there is one particular presidential hometown that is unique in what it has to offer those who make the trip.
Video

Video The Legacy of Jimmy Carter: The Preacher from Plains

It is common in the United States to see tourists flock to sites associated with America's presidents. Some are privately owned and others are run by the National Park Service or the National Archives -- but most have helped draw business and people into the towns and cities where they are located. As VOA’s Kane Farabaugh reports, there is one particular presidential hometown that is unique in what it has to offer those who make the trip.
Video

Video Hong Kong Protests Draw New Supporters on National Holiday

On the 65th anniversary of the founding of Communist China, Hong Kong protesters are hoping to stage the largest pro-democracy demonstration since the 1989 Tiananmen protests. VOA's Brian Padden visited one of the protest sites mid-day, when the atmosphere was calm and where the supporters were enthusiastic about joining what they are calling the umbrella revolution.
Video

Video India's PM Continues First US Visit

India's prime minister is on his first visit to Washington, to strengthen political and economic ties between the world's oldest and the world biggest democracies. He came to the U.S. capital from New York, the first stop on his five-day visit to the country that denied him an entry visa in the past. From Washington, Zlatica Hoke reports Modi seemed most focused on attracting foreign investment and trade to increase job opportunities for his people.
Video

Video Malaysia Struggles to Stop People Joining Jihad

Malaysian authorities say militant groups like the so-called "Islamic State" have used social media to entice at least three dozen Malaysian Muslims to fight in what they call "jihad" in Syria and Iraq. As Mahi Ramkrishnan reports from Kuala Lumpur, counterterrorism police are deeply worried about what could happen when these militants return home.
Video

Video Could US Have Done More to Stop Rise of Islamic State?

President Obama says airstrikes against Islamic State militants in Syria will likely continue for some time because, in his words, "there is a cancer that has grown for too long." So what if President Obama had acted sooner in Syria to arm more-moderate opponents of both the Islamic State and the Syrian government? VOA State Department Correspondent Scott Stearns reports from the United Nations.
Video

Video Treasure Hunters Seek 'Hidden Treasure' in Central Kenya

Could a cave in a small village in central Kenya be the site of buried treasure? A rumor of riches, left behind by colonialists, has some residents dreaming of wealth, while others see it as a dangerous hoax. VOA's Gabe Joselow has the story.
Video

Video Ebola Patients Find No Treatment at Sierra Leone Holding Center

At a holding facility in Makeni, central Sierra Leone, dozens of sick people sit on the floor in an empty university building. They wait in filthy conditions. It's a 16-hour drive by ambulance to Kailahun Ebola treatment center. Adam Bailes was there and reports on what he says are some of the worst situations he has seen since the beginning of this Ebola outbreak. And he says it appears case numbers may already be far worse than authorities acknowledge.
Video

Video Identifying Bodies Found in Texas Border Region

Thousands of immigrants have died after crossing the border from Mexico into remote areas of the southwestern United States in recent years. Local officials in south Texas alone have found hundreds of unidentified bodies and buried them in mass graves in local cemeteries. Now an anthropologist and her students at Baylor University have been exhuming bodies and looking for clues to identify them. VOA’s Greg Flakus has more from Waco, Texas.
Colonel Steve ‘Spiros’ Pisanos left Greece and came to the U.S. to learn to fly. He flew fighters for the Allies in World War II, narrowly escaping death multiple times.Colonel Steve ‘Spiros’ Pisanos left Greece and came to the U.S. to learn to fly. He flew fighters for the Allies in World War II, narrowly escaping death multiple times.

AppleAndroid